Retigabine filings completed in the US and Europe

Retigabine filings completed in the US and Europe 

Meda's partner for Retigabine, Valeant Pharmaceuticals, today announced that
Retigabine completed both the New Drug Application (NDA) and the Marketing
Authorisation Application (MAA) submissions on October 30, 2009. 

Retigabine comprises a new way of affecting potassium channels in the central
nervous system. It has been documented to treat epilepsy and has a different
mechanism of action compared to current antiepileptic therapies. 

The pharmaceutical company GlaxoSmithKline has signed a worldwide collaboration
agreement with Valeant Pharmaceuticals for the Retigabine substance. Meda is
entitled to receive significant royalties and certain milestone payments on the
Retigabine substance.

If questions, please contact:

Anders Larnholt, Vice President Corporate Development & IR	ph: +46 709-458 878


MEDA AB (publ) is a leading international specialty pharma company. Meda's
products are sold in 120 countries worldwide and the company is represented by
its own organizations in more than 40 countries. The Meda share is listed under
Large Cap on the Nasdaq OMX Nordic Stock Exchange in Stockholm. Find out more,
visit www.meda.se.